Andrew Wardley
Overview
Explore the profile of Andrew Wardley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
4311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, et al.
J Clin Oncol
. 2020 Sep;
38(34):3987-3998.
PMID: 32954927
Purpose: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with...
12.
Lin N, Borges V, Anders C, Murthy R, Paplomata E, Hamilton E, et al.
J Clin Oncol
. 2020 May;
38(23):2610-2619.
PMID: 32468955
Purpose: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib....
13.
Rothe F, Silva M, Venet D, Campbell C, Bradburry I, Rouas G, et al.
Clin Cancer Res
. 2019 Mar;
25(12):3581-3588.
PMID: 30862692
Purpose: In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each therapy alone. Biomarkers allowing to predict treatment response...
14.
Cameron D, Morden J, Canney P, Velikova G, Coleman R, Bartlett J, et al.
Lancet Oncol
. 2017 Jun;
18(7):929-945.
PMID: 28600210
Background: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated...
15.
Earl H, Vallier A, Dunn J, Loi S, Ogburn E, McAdam K, et al.
Br J Cancer
. 2016 Nov;
115(12):1462-1470.
PMID: 27875516
Background: We report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer. Methods: Clinical cardiac events were defined...
16.
Rugo H, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, et al.
Breast Cancer Res Treat
. 2013 May;
139(2):411-9.
PMID: 23649189
The aim of this phase II trial was to estimate the objective response rate (ORR) of two different schedules of ixabepilone [weekly or every 3 weeks (Q3W)] combined with bevacizumab,...
17.
Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, et al.
J Clin Oncol
. 2013 Apr;
31(14):1719-25.
PMID: 23569311
PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor...
18.
Pestalozzi B, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al.
Lancet Oncol
. 2013 Feb;
14(3):244-8.
PMID: 23414588
Background: Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer. However, concern has been expressed that adjuvant trastuzumab might be associated with...
19.
Mackey J, Martin M, Pienkowski T, Rolski J, Guastalla J, Sami A, et al.
Lancet Oncol
. 2012 Dec;
14(1):72-80.
PMID: 23246022
Background: We compared standard adjuvant anthracycline chemotherapy with anthracycline-taxane combination chemotherapy in women with operable node-positive breast cancer. Here we report the final, 10-year follow-up analysis of disease-free survival, overall...
20.
Ferraldeschi R, Arnedos M, Hadfield K, AHern R, Drury S, Wardley A, et al.
Breast Cancer Res Treat
. 2012 Mar;
133(3):1191-8.
PMID: 22418701
Single nucleotide polymorphisms (SNPs) in the gene encoding aromatase (CYP19A1) have been associated with differential benefit from letrozole treatment in metastatic breast cancer (mBC) patients, but validation is lacking. The...